NASHVILLE, Tenn., Feb 24, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") announced today that Company management will participate in Citi's Global Property CEO Conference March 4, 2025 and Barclays Global Healthcare Conference on March 11, 2025.
On March 4, at the Citi Conference, the Brookdale fireside chat will begin at 7:10 am CST, and the live webcast can be accessed through the Company's website at brookdaleinvestors.com as well as by clicking here.
On March 11, at the Barclays Healthcare Conference, the Brookdale fireside chat will begin at 8:30 am CST, and the live webcast can be accessed through the Company's website as well as by clicking here.
A replay of the webcasts will be available on the Company's website until May 2, 2025.
About Brookdale Senior Living
Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. With 647 communities across 41 states and the ability to serve approximately 58,000 residents as of December 31, 2024, Brookdale is committed to its mission of enriching the lives of seniors through compassionate care, clinical expertise, and exceptional service. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities, offering tailored solutions that help empower seniors to live with dignity, connection, and purpose. Leveraging deep expertise in healthcare, hospitality, and real estate, Brookdale creates opportunities for wellness, personal growth, and meaningful relationships in settings that feel like home. Guided by its four cornerstones of passion, courage, partnership, and trust, Brookdale is committed to delivering exceptional value and redefining senior living for a brighter, healthier future. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.
Last Trade: | US$6.58 |
Daily Change: | 0.01 0.15 |
Daily Volume: | 2,256,810 |
Market Cap: | US$1.310B |
April 08, 2025 January 09, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load